Daiichi Sankyo Co. Ltd.

Company Snapshot

Founded: 2005
Entity Type: Public
Employees: 20,171
Region: Japan
Revenue: $14,107.6 Millions
Revenue Year: 2025
Headquarter: Japan
Key Geographics: North America, Europe, Japan, Other Regions
Corporate Address: 3-5-1, Nihonbashi-honcho Chuo-ku, Tokyo 103-8426 Japan 81-3-6225-1111 www.daiichisankyo.com

Company Overview

Daiichi Sankyo Co. Ltd. is a global pharmaceutical company formed in 2005 through the merger of two established Japanese drugmakers. It researches, develops, manufactures, markets, and sells a range of pharmaceutical products, including prescription medicines, over-the-counter (OTC) products, vaccines, veterinary medicines, and medical equipment. Its portfolio covers treatments for cardiovascular diseases, oncology (cancer), metabolic conditions, infectious diseases, neurological disorders, and more.

Financial Highlights (FY 2025)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

Daiichi Sankyo Co. Ltd. In Reports

Cardiovascular Drugs: Global Markets to 2030

BCC Research detailed report on cardiovascular drugs market global revenue ($ million) for the base year 2024 and estimated data for the forecast period 2025 through 2030.

Neuroprotective Agents: Therapeutic Applications and Global Markets

Our detailed report on neuroprotective agent market revenue ($ Million) for the base year of 2024 and estimated data for 2025 and the forecast period 2026 through 2030.

Global Pharmaceutical Drugs Industry: Competitive Landscape 2023

BCC Research Report: Dive into pharmaceutical drugs market dynamics, competitive intelligence, and regional trends are well-researched and analyzed in this report.

Company's Business Segments

  • Pharmaceutical Operation : Under this segment, the company provides Oncology, Cardiovascular, Other Pharmaceuticals, and Vaccines.

Applications/End User Industries

  • Healthcare
  • Pharmaceuticals
  • Life Sciences
AI Sentiment